[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613168":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":52,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":21,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":18,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Rochester","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention (CHORDS)","EXPERIMENTAL","The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).",[13],"Other: CHORDS",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","NO_INTERVENTION","Patients randomized to the usual care arm will receive standard of care. Patients (and their caregivers when available) randomized to usual care will not participate in CHORDS. Patients and caregivers will complete baseline (T1) and post-alloHCT office visit (T3, T4, T5) assessments.",null,[20],{"type":6,"name":21,"description":11,"armGroupLabels":22,"otherNames":18},"CHORDS",[9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Rachel Rodenbach, MD, MS","CONTACT","585-275-5830","rachel_rodenbach@urmc.rochester.edu",{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},"Becky Gravenstede, BA","585-727-4728","becky_gravenstede@urmc.rochester.edu",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Rochester","New York","14642","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-77.61556,43.15478,{"lat":45,"lon":44},[48,50],{"name":49,"role":26,"phone":27,"phoneExt":18,"email":28},"Rachel Rodenbach",{"name":49,"role":51,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":49,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Assistant Professor - Department of Medicine, Hematology\u002FOncology (SMD)","100613168","considering-allohct-opportunities-for-patient-reflection-during-decision-making-via-digital-stories-100613168",false,"NCT07263074","Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories","Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation","Patients\n\nInclusion criteria:\n\n1. Age \\>21 years old\n2. Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS\u002FMPN)\n3. Being considered for alloHCT\n4. Able to provide informed consent\n5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated.\n\nExclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures\n\nCaregivers\n\nInclusion criteria:\n\n1. Age \\>18 years old\n2. Selected by the patient when asked if there is a \"family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters.\"\n3. Caregiver may be paid\u002Fprofessional or informal caregiver\n4. Able to provide informed consent\n5. Able to speak English\n\nExclusion Criteria:\n\n1\\) None\n\nHematologists\n\nInclusion criteria:\n\n1\\) Hematologists of the patients who agree to enroll on the study who are part of Wilmot Cancer Institute.\n\nExclusion criteria\n\n1\\) None","ALL","21 Years",{"count":64,"type":65},120,"ESTIMATED","INTERVENTIONAL",[68],"NA","This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \\[CHORDS\\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).",[71],"Myeloid Malignancy","2026-03-27",{"date":74,"type":75},"2026-03-30","ACTUAL",{"date":77,"type":75},"2026-01-15",{"date":79,"type":65},"2028-06-30",{"name":5,"class":6},1]